Please use this identifier to cite or link to this item:
|Title:||Management of early stage gastro-oesophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty.||Austin Authors:||Roy, Amitesh C;Shapiro, Jeremy;Burge, Matt;Karapetis, Christos S;Pavlakis, Nick;Segelov, Eva;Chau, Ian;Lordick, Florian;Chen, Li-Tong;Barbour, Andrew;Tebbutt, Niall;Price, Tim||Affiliation:||University Cancer Centre Leipzig, Leipzig University Medical Centre, Leipzig, Germany
Cabrini Health, Monash University, Melbourne, Australia
Queen Elizabeth Hospital/University of Adelaide, Adelaide, Australia
Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
The University of Queensland Diamantina Institute, the University of Queensland, Woolloongabba, QLD, Australia
Department of Medical Oncology, Monash University and Monash Health, Melbourne 3800, Australia
Department of Medical Oncology, Royal North Shore Hospital, Sydney 2065, Australia
Flinders Centre For Innovation in Cancer/Flinders University, Bedford Park, South Australia, 5042, Australia
Department of Cancer Care Services, Royal Brisbane Hospital, University Of Queensland, Herston, Queensland..
Dept. of Medical Oncology, Royal Marsden Hospital, Institute of Cancer Research, Surrey, London, UK, SM2 5PT..
National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan..
|Issue Date:||21-Mar-2020||metadata.dc.date:||2020||Publication information:||Expert review of anticancer therapy 2020; online first: 21 March||Abstract:||Introduction: A multimodal approach in operable early stage oesophago-gastric (OG) cancer has evolved in the last decade, leading to improvement in overall outcomes.Areas covered: A review of the published literature and conference abstracts was undertaken on the topic of optimal adjunctive chemotherapy or chemoradiotherapy in early stage OG cancers. This review article focuses on the current evidence pertaining to neo-adjuvant and perioperative strategies in curable OG cancers including the evolving landscape of immunotherapy and targeted drugs in this setting.Expert commentary: Adjunctive therapies in the form of pre-operative chemo-radiotherapy (CRT) or chemotherapy and perioperative chemotherapy over surgery alone improves outcomes in patients with operable OG cancer. Although there are variations in practice around the world, a multi-disciplinary approach to patient care is of paramount importance. Immunotherapy and on treatment functional imaging are two examples of emerging strategies to improve outcome for early stage patients. Better understanding of the molecular biology of this disease may help overcome the problem of tumour heterogeneity and enable more rationally designed and targeted therapeutic interventions in the future.||URI:||http://ahro.austin.org.au/austinjspui/handle/1/22893||DOI:||10.1080/14737140.2020.1746185||ORCID:||0000-0002-3922-2693||PubMed URL:||32202178||Type:||Journal Article|
|Appears in Collections:||Journal articles|
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.